# Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

> **NCT00675025** · PHASE2 · TERMINATED · sponsor: **Eisai Inc.** · enrollment: 117 (actual)

## Conditions studied

- Down Syndrome

## Interventions

- **DRUG:** Donepezil hydrochloride (Aricept)

## Key facts

- **NCT ID:** NCT00675025
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04-04
- **Primary completion:** 2008-11-13
- **Final completion:** 2008-12-15
- **Target enrollment:** 117 (ACTUAL)
- **Why stopped:** Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.
- **Last updated:** 2021-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00675025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00675025, "Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00675025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*